Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma

European Journal of Haematology

Volumn 88, Issue 6, 2012, Pages 497-503

  El Cheikh, Jean ^a   Crocchiolo, Roberto ^a   Boher, Jean Marie ^a   Furst, Sabine ^a   Stoppa, Anne Marie ^a   Ladaique, Patrick ^a   Faucher, Catherine ^a   Calmels, Boris ^a   Castagna, Luca ^a   Lemarie, Claude ^a   De Colella, Jean Marc Schiano ^a   Coso, Diane ^a   Bouabdallah, Reda ^a   Chabannon, Christian ^a   Blaise, Didier ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Multiple myeloma; Reduced intensity conditioning; Unrelated donor

Indexed keywords

ALKYLATING AGENT; AMOXICILLIN; BORTEZOMIB; BUSULFAN; COTRIMOXAZOLE; CYCLOSPORIN A; DEXAMETHASONE; FLUDARABINE; GANCICLOVIR; LENALIDOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THALIDOMIDE; THYMOCYTE ANTIBODY; VALACICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; FOLLOW UP; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; MALE; MATCHED RELATED DONOR; MULTIPLE MYELOMA; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; TOXOPLASMOSIS; TREATMENT OUTCOME; UNRELATED DONOR; WHOLE BODY RADIATION;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84861190044     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01777.x     Document Type: Article

References (26)

1. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2011.
2. Blade J, Rosinol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010;115:3655-63.
3. Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010;28:4521-30.
4. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002;100:3919-24.
5. Kroger N. Unrelated stem cell transplantation for patients with multiple myeloma. Curr Opin Hematol 2010;17:538-43.
6. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005;105:4532-9.
7. El-Cheikh J, Michallet M, Nagler A, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008;93:455-8.
8. Lioznov M, El-Cheikh J Jr., Hoffmann F, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010;45:349-53.
9. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-9.
10. De Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008;41:953-60.
11. Kroger N. Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma. Leuk Lymphoma 2005;46:813-21.
12. Kroger N, Shimoni A, Schilling G, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol 2010;148:323-31.
13. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-54.
14. Kroger N, Einsele H, Wolff D, et al. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). Bone Marrow Transplant 2003;31:973-9.
15. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Ass 1958;53:457-81.
16. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
17. Ballen KK, King R, Carston M, Kollman C, Nelson G, Lim S, Reece D, Giralt S, Vesole DH. Outcome of unrelated transplants in patients with multiple myeloma. Bone Marrow Transplant 2005;35:675-81.
18. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, Chauncey T, Shulman H, Appelbaum FR. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2787-93.
19. Shaw BE, Peggs K, Bird JM, et al. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. Br J Haematol 2003;123:886-95.
20. Georges GE, Maris MB, Maloney DG, et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007;13:423-32.
21. Bruno B, Sorasio R, Patriarca F, et al. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. Eur J Haematol 2007;78:330-7.
22. Ho VT, Kim HT, Aldridge J, et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1196-204.
23. Richa E, Papari M, Allen J, Martinez G, Wickrema A, Anastasi J, van BK, Artz A. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2009;15:1394-9.
24. Baron F, Storer B, Maris MB, et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006;12:1176-87.
25. Carreras E, Jimenez M, Gomez-Garcia V, et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 2006;37:33-40.
26. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001;98:2043-51.